Effects of methylphenidate on the development of the dopaminergic system in the brai
- Conditions
- attention deficit hyperactivity disorder (ADHD)attention disorder1000984110042258
- Registration Number
- NL-OMON39033
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
50 adolescent (10-12 years of age) and 50 adult (23-40 years of age) male outpatients diagnosed with type ADHD, all subtypes as defined in the DSM-IV, and in need of pharmacotherapy according to existing guidelines.
-Co-morbid Axis I psychiatric disorders requiring treatment with medication at study entry, and a history of epilepsy and traumatic brain injury. ;-IQ < 70 (subtest Wechsler Intelligence Scale for children-Revised (WISC-R; Wechsler 1981) or National Adult Reading Test (NART; Nelson 1991, Dutch translation Schmand et al. 1991) ;- Current or previous treatment with medications that influence the DA system (for adults before 23 years of age) such as: neuroleptics, antipsychotics, D2/D3 agonists (pramipexole and ropinirole);-Current or previous (ab)use of drugs that influence the DA system (for adults before 23 years of age), such as: MDMA, amphetamine, methamphetamine, cocaine, heroine and LSD ;-Contraindications to MPH treatment: cardiovascular diseases such as hypertension, arrhythmia, hyperthyroidism, glaucoma, suicidality, psychosis, Tourette disorder.;-Prenatal use of MPH by mother of the patients.;-Contraindications to MRI (metal implants, pacemakers, claustrophobia, etc.)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method